Atrium Therapeutics Reports Third Quarter 2026 Financial Results

First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome ---- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome ---- Pro-forma cash balance at the end of September 2026 was $293.6 million with a…